Search results for "ANGIOPLASTY"

showing 10 items of 201 documents

Recommendations for the management of patients with aneurysmal subarachnoid hemorrhage

2005

After SAH, primary and secondary complications are frequent and often require neurosurgical interventions to avoid secondary brain damage. The authors of the present paper have summarized the available data about the treatment modalities often used for patients with SAH. The present recommendations have been developed as a neurosurgical and neuroanestesiological consensus. Evidence from prospective, randomized, double blind, placebo-controlled studies support grade A recommendations (standard) for the prophylaxis and treatment of cerebral vasospasm with oral Nimodipine in good grade patients. For intravenous Nimodipine or for oral nimodipine treatment in poor grade patients, available data …

medicine.medical_specialtySubarachnoid hemorrhagemedicine.medical_treatmentNeurosurgeryBrain damageCerebral vasospasmGermanyAngioplastyHypovolemiaHumansVasospasm IntracranialMedicineProspective cohort studyNimodipineRandomized Controlled Trials as Topicbusiness.industrySubarachnoid Hemorrhagemedicine.diseaseSurgeryAnesthesiaSurgeryNeurology (clinical)medicine.symptombusinessHypervolemiaAngioplasty Balloonmedicine.drugNeurochirurgie
researchProduct

Impact of prehospital delay on mortality in patients with acute myocardial infarction treated with primary angioplasty and intravenous thrombolysis.

2001

Abstract Background In patients with acute myocardial infarction treated with thrombolysis, longer times to treatment are associated with increasingly worse clinical outcome. This relation may be different for treatment with primary angioplasty. Methods We analyzed the pooled data of the German acute myocardial infarction registries Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) and Myocardial Infarction Registry (MIR) to determine the influence of prehospital delays on hospital mortality rates. Primary angioplasty was performed in 1063 patients and thrombolysis in 7552 patients. Results In patients treated with thrombolysis, in-hospital time to treatment was constantly 3…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentTime to treatmentPrimary angioplastyMyocardial InfarctionStatistics NonparametricInternal medicineFibrinolysismedicineHumansIn patientThrombolytic TherapyMyocardial infarctionHospital MortalityProspective StudiesRegistriesChemotherapyChi-Square Distributionbusiness.industryMortality rateThrombolysisMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeCardiologyFemaleCardiology and Cardiovascular MedicinebusinessAngioplasty BalloonAmerican heart journal
researchProduct

Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated hep…

2003

Item does not contain fulltext OBJECTIVES: The aim of this study was to evaluate percutaneous coronary intervention (PCI) in the Assessment of the Safety and Efficacy of New Thrombolytic Regimens (ASSENT-3) trial. BACKGROUND: In the ASSENT-3 trial, co-therapy with abciximab (ABC) or enoxaparin (ENOX) reduced ischemic complications after ST-elevation acute myocardial infarction treated with tenecteplase when compared with unfractionated heparin (UFH). The effect of these new co-therapies on the results of PCI is unknown. METHODS: Clinical outcomes in patients who received co-therapy with ABC, ENOX, or UFH and subsequently underwent an elective (n = 1,064) or urgent (n = 716) PCI in the ASSEN…

MaleAbciximabmedicine.medical_treatmentMyocardial InfarctionAlbertaBelgiumRecurrenceGermanyAbciximabAngioplasty Balloon CoronaryHeart lung and circulation [UMCN 2.1]Netherlandseducation.field_of_studyAntibodies MonoclonalMiddle AgedTreatment OutcomeItalyElective Surgical ProceduresTissue Plasminogen ActivatorDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicineEnoxaparin sodiummedicine.drugmedicine.medical_specialtymedicine.drug_classPopulationLow molecular weight heparinTenecteplasePlatelet Glycoprotein GPIIb-IIIa ComplexDrug Administration ScheduleImmunoglobulin Fab FragmentsFibrinolytic AgentsInternal medicineNorth CarolinamedicineHumansEnoxaparineducationEmergency TreatmentSwedenHeparinbusiness.industryAnticoagulantsPercutaneous coronary interventionSurvival AnalysisSurgerySpainConventional PCITenecteplasebusinessFibrinolytic agentJournal of the American College of Cardiology
researchProduct

Primary endpoint results of the OMEGA Study: One-year clinical outcomes after implantation of a novel platinum chromium bare metal stent.

2014

Bare metal stents (BMS) have similar rates of death and myocardial infarction (MI) compared to drug-eluting stents (DES). DES lower repeat revascularization rates compared to BMS, but may have higher rates of late stent thrombosis (ST) potentially due to impaired endothelialization requiring longer dual anti-platelet therapy (DAPT). OMEGA evaluated a novel BMS designed to have improved deliverability and radiopacity, in comparison to currently available platforms.OMEGA was a prospective, multicenter, single-arm study enrolling 328 patients at 37 sites (US and Europe). Patients received the OMEGA stent (bare platinum chromium element stent) for the treatment of de novo native coronary artery…

Bare-metal stentTarget lesionChromiumMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentRevascularizationCoronary AngiographyProsthesis DesignRisk AssessmentSeverity of Illness IndexCoronary artery diseaseCoronary RestenosisInternal medicineClinical endpointMedicineHumansSingle-Blind MethodMyocardial infarctionProspective StudiesAngioplasty Balloon CoronaryAgedPlatinumAged 80 and overbusiness.industryCoronary StenosisStentGeneral MedicineMiddle Agedmedicine.diseaseSurgerySurvival Ratemedicine.anatomical_structureTreatment OutcomeMetalsCardiologyFemaleStentsPatient SafetyCardiology and Cardiovascular MedicinebusinessArteryFollow-Up StudiesCardiovascular revascularization medicine : including molecular interventions
researchProduct

Long-term outcomes of percutaneous coronary interventions or coronary artery bypass grafting for left main coronary artery disease in octogenarians (…

2014

Percutaneous coronary intervention (PCI) with drug-eluting stents is an accepted alternative to surgery for the treatment of unprotected left main coronary artery (ULMCA) disease, but the long-term outcome in elderly patients is unclear. Aim of our study was to compare the clinical outcomes of octogenarians with ULMCA disease treated either with PCI with drug-eluting stents or coronary artery bypass grafting (CABG). The primary study end point was the composite of death, cerebrovascular accident, and myocardial infarction at follow-up. A total of 304 consecutive patients with ULMCA stenosis treated with PCI or CABG and aged 80 years were selected and analyzed in a large multinational regist…

Malemedicine.medical_treatmentMedizinCoronaryKaplan-Meier EstimateCoronary AngiographyCohort StudiesPostoperative Complications80 and overMyocardial infarctionHospital MortalityRegistriesSurvivorsAngioplasty Balloon CoronaryCoronary Artery BypassAged 80 and overEjection fractionHazard ratioAge FactorsAge Factors; Aged 80 and over; Angioplasty Balloon Coronary; Cohort Studies; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Coronary Vessels; Female; Geriatric Assessment; Hospital Mortality; Humans; Kaplan-Meier Estimate; Male; Percutaneous Coronary Intervention; Postoperative Complications; Prognosis; Propensity Score; Registries; Retrospective Studies; Risk Assessment; Survival Analysis; Survivors; Treatment Outcome; Drug-Eluting Stents; Cardiology and Cardiovascular MedicineDrug-Eluting StentsPrognosisCoronary Vesselssurgical procedures operativeTreatment OutcomeDrug-eluting stentCardiologyFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyRevascularizationRisk AssessmentPercutaneous Coronary InterventionInternal medicineAngioplastymedicineHumanscardiovascular diseasesPropensity ScoreGeriatric AssessmentAgedRetrospective Studiesbusiness.industryAngioplastyCoronary StenosisPercutaneous coronary interventionmedicine.diseaseSurvival AnalysisSurgeryConventional PCIbusinessBalloon
researchProduct

Multicenter and all-comers validation of a score to select patients for manual thrombectomy, the DDTA score.

2021

Background Routine manual thrombectomy (MT) is not recommended in primary percutaneous coronary intervention (P-PCI) but it is performed in many procedures. The objective of our study was validating the DDTA score, designed for selecting patients who benefit most from MT. Methods Observational and multicenter study of all consecutive patients undergoing P-PCI in five institutions. Results were compared with the design cohort and the performance of the DDTA was analyzed in all patients. Primary end-point of the analyses was TIMI 3 after MT; secondary endpoints were final TIMI 3, no-reflow incidence, in-hospital mortality and in-hospital major cardiovascular events (MACE). In-hospital prognos…

medicine.medical_specialtymedicine.medical_treatmentMyocardial Infarction030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionInternal medicineMedicineHumansRadiology Nuclear Medicine and imagingIn patient030212 general & internal medicinecardiovascular diseasesEdetic AcidThrombectomyPrimary angioplastyFramingham Risk Scorebusiness.industryIncidence (epidemiology)Percutaneous coronary interventionGeneral MedicineTreatment OutcomeMulticenter studyCohortCardiology and Cardiovascular MedicinebusinessTIMIMace
researchProduct

Argatroban for elective percutaneous coronary intervention: The ARG-E04 multi-center study

2011

The synthetic arginine-derived direct thrombin inhibitor argatroban is an attractive anticoagulant for percutaneous coronary intervention (PCI), because of its rapid onset and offset, and its hepatic elimination. Argatroban was approved for PCI in patients with heparin-induced thrombocytopenia (HIT). However, there are limited data about argatroban in non-HIT patients. The objective of this open-label, multiple-dose, controlled study was to examine the safety and efficacy of argatroban in patients undergoing elective PCI.Of 140 patients randomized to three argatroban dose groups (ARG250, ARG300, and ARG350 with 250, 300, or 350 μg/kg bolus, followed by 15, 20, or 25 μg/kg/min infusion) and …

Malemedicine.drug_classmedicine.medical_treatmentActivated clotting timeHemorrhageArginineAntithrombinsArgatrobanBolus (medicine)medicineHumansAngina UnstableMyocardial infarctionAngioplasty Balloon CoronaryBlood CoagulationAgedSulfonamidesDose-Response Relationship Drugmedicine.diagnostic_testHeparinbusiness.industryAnticoagulantAnticoagulantsPercutaneous coronary interventionThrombosisMiddle Agedmedicine.diseaseDirect thrombin inhibitorPipecolic AcidsAnesthesiaConventional PCIFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up Studiesmedicine.drugInternational Journal of Cardiology
researchProduct

Aktuelle Komplikationsrate der perkutanen transluminalen Koronarangioplastie bei stabiler und unstabiler Angina

2008

During a four-year period (1983-1986) percutaneous transluminal coronary angioplasty (PTCA) was performed on 930 patients with stable or unstable angina with a mortality rate of 0.4%. A transmural myocardial infarct developed in 1.1% and 1.0% of patients required an urgent aorto-coronary bypass. Thus the total rate of severe cardiac complications was 2.5%. Compared with the years 1983-1985, there was in 1986 a significant fall in the number of deaths and of myocardial infarcts from 2.2% to 0.5% (P less than 0.05), while there was a nonsignificant increase in emergency coronary bypass surgery from 0.7 to 1.3%. Patients with unstable angina compared with those with stable angina had a signifi…

medicine.medical_specialtybusiness.industryUnstable anginaIncidence (epidemiology)Mortality ratemedicine.medical_treatmentInfarctionGeneral Medicinemedicine.diseaseAnginaBypass surgeryInternal medicineAngioplastyCardiologyMedicinecardiovascular diseasesMyocardial infarctionbusinessDMW - Deutsche Medizinische Wochenschrift
researchProduct

Development of a coronary aneurysm 6 months after stent implantation assessed by intracoronary ultrasound.

1996

Malemedicine.medical_specialtyArterial diseasemedicine.medical_treatmentCoronary DiseaseAneurysmmedicineStent implantationHumansAngioplasty Balloon CoronaryUltrasonographyVascular diseasebusiness.industryCoronary AneurysmStentMiddle Agedmedicine.diseaseCoronary VesselsCoronary heart diseaseSurgeryIntracoronary ultrasoundStentsRadiologyCardiology and Cardiovascular MedicinebusinessComplicationAmerican heart journal
researchProduct

Efficacy and one-year outcomes of Luminor® paclitaxel-coated drug-eluting balloon in the treatment of popliteal artery atherosclerosis lesions

2021

Purpose: Reporting outcomes with a new generation paclitaxel eluting balloon (Luminor®; iVascular, Vascular, S.L.U., Barcelona, Spain) in the popliteal district. Endovascular treatment of popliteal artery atherosclerotic disease is still debated without definitive evidences. Methods: From January to June 2019, patients’ data presenting popliteal artery atherosclerotic diseases and treated with the Luminor® (iVascular) drug eluting balloon (DEB) were prospectively collected. Critical limb ischemia (CLI) or severe claudication associated with popliteal artery stenosis >50% were the inclusion criteria. Measured outcomes were technical success, early and late results; including mortality, mo…

MaleTime Factorsmedicine.medical_treatmentConstriction Pathologic030204 cardiovascular system & hematologySeverity of Illness IndexSettore MED/22 - Chirurgia Vascolare030218 nuclear medicine & medical imaging0302 clinical medicineRestenosisCoated Materials BiocompatibleIschemiaRecurrenceMedicineProspective StudiesAged 80 and overEndovascularCritical limb ischemiaGeneral MedicineEquipment DesignLimb SalvagePlaque AtheroscleroticTreatment OutcomeFemalemedicine.symptomCardiology and Cardiovascular MedicineVascular Access Devicesmedicine.medical_specialtyPaclitaxelPopliteal arteryCritical IllnessDrug eluting balloonAmputation Surgical03 medical and health sciencesPeripheral Arterial Diseasemedicine.arteryAngioplastyHumansVascular PatencyAgedbusiness.industryAngioplastyCardiovascular AgentsCritical limb ischemiaPerioperativeIntermittent Claudicationmedicine.diseasePopliteal arterySurgeryStenosisAmputationSurgerybusinessClaudicationAngioplasty Balloon
researchProduct